Shares of Sanofi SA (NYSE:SNY) have been given a consensus recommendation of “Buy” by the thirteen analysts that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $49.67.

SNY has been the subject of several analyst reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Tuesday, August 6th. UBS Group upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a report on Wednesday, August 14th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Thursday, August 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research note on Thursday, August 29th. Finally, Sanford C. Bernstein began coverage on shares of Sanofi in a report on Tuesday, September 3rd. They set an “outperform” rating and a $52.00 price objective for the company.

In other news, major shareholder Sanofi purchased 93,750 shares of Sanofi stock in a transaction on Monday, July 22nd. The stock was purchased at an average price of $16.00 per share, with a total value of $1,500,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.00% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Fisher Asset Management LLC raised its holdings in shares of Sanofi by 2.2% in the 2nd quarter. Fisher Asset Management LLC now owns 16,868,423 shares of the company’s stock valued at $729,897,000 after purchasing an additional 367,961 shares during the period. FMR LLC raised its position in shares of Sanofi by 1.9% in the first quarter. FMR LLC now owns 9,233,558 shares of the company’s stock valued at $408,862,000 after purchasing an additional 175,580 shares during the period. Morgan Stanley lifted its stake in shares of Sanofi by 34.1% during the 2nd quarter. Morgan Stanley now owns 3,145,435 shares of the company’s stock worth $136,104,000 after buying an additional 800,612 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Sanofi by 47,594.3% during the 1st quarter. Lazard Asset Management LLC now owns 2,384,716 shares of the company’s stock worth $105,595,000 after buying an additional 2,379,716 shares during the period. Finally, Northern Trust Corp increased its position in Sanofi by 2.5% during the 2nd quarter. Northern Trust Corp now owns 2,275,495 shares of the company’s stock worth $98,461,000 after buying an additional 56,394 shares during the period. Hedge funds and other institutional investors own 7.04% of the company’s stock.

SNY stock traded down $0.03 during midday trading on Friday, reaching $43.53. The stock had a trading volume of 85,009 shares, compared to its average volume of 1,235,736. The business has a fifty day simple moving average of $42.56 and a two-hundred day simple moving average of $42.70. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The firm has a market cap of $109.01 billion, a price-to-earnings ratio of 13.91, a PEG ratio of 2.41 and a beta of 0.67. Sanofi has a twelve month low of $40.00 and a twelve month high of $45.62.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 29th. The company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.07. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm had revenue of $8.63 billion during the quarter, compared to analysts’ expectations of $8.42 billion. During the same period in the previous year, the business posted $1.25 EPS. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, equities analysts predict that Sanofi will post 3.1 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Trade Deficit

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.